Vetter plans to invest $320 million on 10-year expansion plan
Company provides insights into its long-term expansion plans that include the purchasing of property in the City of Des Plaines
At a meeting held on 12 July for interested residents and other stakeholders, officials of the City of Des Plaines and Vetter were given the opportunity to share initial plans for the proposed purchase and development by Vetter of a 18-acre site, located at the corner of Mount Prospect and Algonquin Road. Vetter's initial concept intends to offer its global customer base a US manufacturing opportunity for their market supply needs of commercialised drugs.
Vetter provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of injectable drugs. For this project, the company plans investments of approximately $320 million on construction and site improvements over more than 10 years. Once it has reached its final expansion stage, the 18-acre site would include 1,138,237 sq. ft. of facility space. If approved, the facility would be the second US manufacturing site of the company. The Des Plaines project would complement its existing US clinical development support service offering which consists of a small-scale manufacturing facility located in the nearby Village of Skokie. Des Plaines would be the recipient of several positive outcomes including the creation of approximately 400–500 new jobs by the final expansion stage. Many of these are expected to be hired locally.
“We believe that this project represents a win-win scenario for the residents of Des Plaines and Vetter alike,” said Vetter Managing Director Peter Soelkner. “For us, it would be the next step in our plan for continuous growth. Several of our customers have requested commercial manufacturing resources both in US and Europe for their multi-facetted market production needs. Being in a continuous dialogue with them, such a facility would enlarge Vetter’s geographical manufacturing opportunities, and thus, increase our customer’s flexibility. We are excited about the positive outcomes this project can bring to the city of Des Plaines, and becoming a good and trustworthy neighbour to its residents. Des Plaines is a great partner in the process, we would be happy to receive the projects approval,” said Soelkner.
Founded as a modest pharmacy in Ravensburg, Germany, the company has grown from a local packager to a world-leading contract development and manufacturing organisation, today serving the top 10 (bio-)pharmaceutical companies as well as small and midsize companies. If approved and realised, the facility would complement Vetter’s existing site at the Illinois Science+Technology Park in Skokie which has approximately 70 employees, most of whom are local residents. The purpose and scope of work between the two facilities would not be overlapping, but acting as a complementary service to its customers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance